John Wesley McConnell MD
Critical Care Medicine, Interventional Pulmonology
KPA
100 W Market StSte 2Louisville, KY 40202
Fax+1 502-583-8001
Overview of Dr. McConnell
Dr. John McConnell is a pulmonologist based in Louisville, KY, with subspecialties in Critical Care Medicine and Interventional Pulmonology. He completed his medical education at the Medical College of Georgia at Augusta University, followed by a residency in Internal Medicine and a fellowship in Pulmonary Disease and Critical Care Medicine at the University of Kentucky College of Medicine. Dr. McConnell has experience in transplant pulmonology, critical care medicine, tracheal intubation, ventilation management, and pulmonary vascular disease. His published work covers various aspects of pulmonary arterial hypertension and chronic disease management, with multiple articles cited in academic circles. He has also been involved in several clinical trials related to pulmonary hypertension. Among his recognitions are the Top MD award from Consumers Checkbook and CMS Meaningful Use Stage 1 Certifications from Allscripts.
Education & Training
University of Kentucky College of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 1985 - 1988- University of Kentucky College of MedicineResidency, Internal Medicine, 1982 - 1985
Medical College of Georgia at Augusta UniversityClass of 1982
Certifications & Licensure
IN State Medical License 1989 - 2027
KY State Medical License 1983 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2012, 2014
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2013
Clinical Trials
- Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
- Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program Start of enrollment: 2011 Jun 01
- Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Start of enrollment: 2012 Jun 26
Publications & Presentations
PubMed
- 1 citationsRiociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies.Marius M Hoeper, Stephan Rosenkranz, David B Badesch, Marc Humbert, David Langleben
Respiratory Medicine. 2025-01-01 - 2 citationsHospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension.John McConnell, S Pinar Bilir, Yifan Xu, Yuen Tsang, Sumeet Panjabi
Journal of Medical Economics. 2023-10-31 - 1 citationsImpact of the COVID-19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Associa...Megan Mayer, David B Badesch, Kelly H Nielsen, Steven Kawut, Todd Bull
Pulmonary Circulation. 2023-04-01
Press Mentions
Lauren Gerlach, M.P.PMay 28th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
